ERNA
$0.27-0.00 (-1.59%)
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease.
Recent News
BC-Most Active Stocks
YY Group Holdings Ltd. 56,330,377 0.4678
Ernexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024)
NasdaqCM:ERNA 1 Year Share Price vs Fair Value Explore Ernexa Therapeutics's Fair Values from the Community and select...
Ernexa Therapeutics announces 1-for-15 reverse stock split
Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common Stock is expected to begin trading on a split-adjusted basis when the market opens on June 12, 2025, under the existing trading symbol “ERNA.” The Company is effecting the reverse split to regain compliance with the $1.00 minimum bid price required for continued